Biocon gets EIR from USFDA for Bengaluru biologics unit Medical Dialogues Bureau6 Nov 2019 3:49 AM GMTNew Delhi: Biopharmaceutical firm Biocon on Tuesday said it has received an establishment inspection report (EIR) from the US health regulator for its...
Biocon, Mylan gets Canadian nod for biosimilar of cancer drug Herceptin Farhat Nasim23 May 2019 6:29 AM GMTOgivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan's joint portfolio approved in the...
AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise Medical Dialogues Bureau10 May 2019 3:30 AM GMTThe treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate Meghna A Singhania11 April 2019 5:20 AM GMTMumbai: In a move that will provide relief to cancer patients, drugmaker Intas Pharmaceuticals has recently announced the launch of Trastuzumab...
AstraZeneca, Daiichi Sankyo sign $6.9 billion cancer drug deal Garima29 March 2019 3:45 AM GMTUnder the deal, AstraZeneca will pay Daiichi up to $6.9 billion, including a $1.35 billion upfront payment. The two companies will share development...
USFDA approves Mylan, Biocon's Fulphila, the first biosimilar to Neulasta Ruby Khatun Khatun6 Jun 2018 5:00 AM GMTHERTFORDSHIRE/PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's...
Roche plea in HC on cancer drug not maintainable: Biocon, Mylan Ruby Khatun Khatun12 Jan 2018 4:57 AM GMTNew Delhi: Generic drug makers Biocon and Mylan told the Delhi High Court that Swiss pharma major Roche's civil suit, challenging DCGI approvals...
EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars Ruby Khatun Khatun2 Dec 2017 4:30 AM GMTHERTFORDSHIRE, England, PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for...
Roche sues Pfizer to bar biosimilar of cancer drug Herceptin Ruby Khatun Khatun22 Nov 2017 4:30 AM GMTRoche Holding AG, facing pressure in Europe as cheaper biosimilars of its three biggest cancer medicines chew away at its revenue, sued to block...
Mylan seeks EMA approval for 2 biosimilars Ruby Khatun Khatun9 Nov 2017 5:02 AM GMTNew Delhi: Biocon said that its partner Mylan has re-submitted marketing authorization applications with the European Medicines Agency for two...
NPPA Slashes price of another 54 Critical medcines. Check out the details Geeta Sharma Sharma14 May 2016 10:35 AM GMTThe common man ailing from critical diseases has received a reliever through the recent National Pharmaceutical Pricing Authority (NPPA) directive to...
